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1. Introduction 
To describe the relation between the nervous system and the heart Natelson, among others, 
coined the term ‘neurocardiology’ in the eighties of the previous century.1 In the nineties, 
the scope of neurocardiology was broadened by researchers from a largely neuroanatomical 
point of view to a focus that was more directed onto interaction between heart and nervous 
system from an integrative physiology focus. Finally, the center of attention of 
neurocardiology also shifted onto experimental science and technology at the neural 
interface of the heart. More specifically, the clinical interest became directed towards basic 
science through studying (modulation of) recruited neuro-humoral, neuro-inflammatory 
and neural pathways, in the presence or absence of angina pectoris, resulting from 
myocardial ischemia.2 
In this respect, the chapter briefly highlights the available conventional therapies for 
ischemic heart diseases, followed by a discussion on efficacy and underlying 
neurocardiological mechanisms of available electrical neuromodulation therapies. In 
addition, a systematic and detailed review is offered on the antiischemic effects of electrical 
neuromodulation in patients with end-stage coronary artery disease. 
2. Ischemic cardiovascular diseases 
The average life span of the Western population has doubled over the last century as a 
consequence of major progress made in developments in socio-economic policies and 
improvements in hygiene. Further, advancements have been accomplished in preventive 
procedures and in the improvement of an armamentarium of therapeutic strategies to 
treat (infectious) diseases. Subsequently, to date in the Western world, civilians are no 
longer subjected to the deleterious menaces of infectious diseases and life expectancy is 
largely determined by atherosclerotic diseases and cancer, each presently representing 1/3 
of all deaths. 
With respect to cardiovascular diseases, as a consequence of preventive measures such as 
life style changes (among others: stopping smoking, increasing physical exercise, eating 
healthy food, reducing stress and treating risk factors), pharmacotherapeutics (nitroglycerin, 
beta-blockers, calcium-antagonists, renin-angiotensin-aldosteron system blockers, lipid 
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lowering drugs, anticoagulants) and revascularization procedures (percutaneous coronary 
interventions [PCI] and coronary artery bypass surgery [CABS]), mortality from 
cardiovascular diseases has declined significantly during the last four decades. As a 
consequence, more patients will survive their heart disease for a longer period. Moreover, 
since the population is graying and therapies have been improved, it is to be expected that 
the number of patients suffering from ischemic heart disease will increase. Ischemic heart 
disease is most often the consequence of atherosclerotic narrowing of one or more coronary 
arteries. During exercise, when the heart muscle demands more oxygen, the shortage in 
oxygen supply, due to the narrowed coronary arteries, provokes chest discomfort, so-called 
angina pectoris. 
2.1 Angina pectoris 
Stable angina is considered as a clinical syndrome, characterized by indistinctly distributed 
chest distress, described as sensations of tightness, pressure, heaviness, squeezing, burning, 
or choking provoked during exercise. The occurrence of angina and its emotional 
components have been brilliantly expressed by Heberden in 1772.3 In acute cardiovascular 
syndromes a coronary artery is closed up and chest discomforts occur at rest, while angina 
is not relieved by nitroglycerin use. Specifically in acute syndromes these symptoms are 
often escorted with vaso-vegetative and emotional sensations such as nausea, transpiration, 
anxiety or thoughts of an impending death. 
To examine the neural pathways, involved in ischemia-induced angina, the heart-brain axis 
is the subject of many years’ thoughtful research on the nervous involvement in cardiac 
control. Following the development of a model for angina, we and others have injected 
analgesic substances, such as bradykinin and capsaicin,4  to study the involved nervous 
pathways, by means of the early gene c-fos.5 Exploration of this neurocardiological field of 
interest has also been focus of behavioral aspects of angina 6 and made the participation of 
the transient receptor potential vanilloid-1 (TRPV-1), at the heart likely.7 Virus tracing 
studies executed by means of a pseudo-rabies virus, injected into the myocardium, made it 
possible to visualize the stained recruited pathways.8,9 See for an overview of our studies on 
neurocardiology reference 10. 
2.2 Chronic refractory angina 
In spite of many innovative developments in pharmacotherapeutic and surgical treatment 
strategies, which have significantly improved life expectancy of patients suffering from 
ischemic heart disease, an increasing number of patients are resistant to all conventional 
opportunities. These patients remain severely disabled and suffer from chest discomfort 
during minimal exercise, or sometimes even at rest. They typically have become refractory 
to maximal tolerated standard anti-ischemic medication and are no longer candidates for 
revascularization procedures, such as PCI and CABS.11 The presence of myocardial ischemia 
should be clinically established to be the cause of symptoms.12  Patients enduring this 
condition are usually characterized by a long history of artery disease, have received at least 
one revascularization(s) procedure(s), are between sixty and seventy years of age, of the 
male gender, experienced one or more myocardial infarction, however, have maintained the 
left ventricular ejection fraction.13  Furthermore, due to progress of their coronary disease, 
these patients most often experience life threatening events such as an acute coronary 
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syndrome and therefore the need of hospital admission.14 The patients have become an 
increasing medical and psychosocial problem resulting from their devastating chest 
discomforts. The impact of the severe complaints of angina on social life and quality of life of 
these patients is often underestimated.15 Whether this is a syndrome that differs from the 
chronic angina patients is doubtful.  
Life expectancy of these patients varies in the literature between 5-8% which may be 
considered as fairly favorable. In this regard, these patients may be considered as survivors 
of their coronary artery disease. It is estimated that the incidence is about 1:10,000 the 
prevalence is 1:30,000 and the total number in the Western World is over 200,000.16 Since 
more patients survive their disease, perceived quality of life issues become more important 
for these patients. Because the patients are severely hindered by their severe angina and 
because conventional treatment options are lacking, the patients have unmet medical needs. 
As a consequence, therapies relieving their angina, without adversely influencing their 
prognosis are imperative. From this point of view, exploration of newer therapies has to be 
promoted with the emphasis on a reduction of both ischemic burden and angina, so that the 
patients may subsequently harvest an improved quality of life. During the last decade for 
patients with surgically and pharmacologically uncontrollable chronic angina, several 
additional therapies have become available,17 of which electrical neuromodulation may be 
considered to be one of the safest, most effective and best evaluated strategies in the current 
therapeutic arsenal, currently available for these patients.18,19 In this regard, electrical 
neuromodulation has become accepted as an adjunct therapy for refractory angina pectoris 
in the ACC/AHA guidelines since 2002.20  
3. Myocardial ischemia (see Fig 1) 
To enhance the metabolism of the muscles during exercise, sufficient oxygen is required. 
The heart receives oxygenated blood from the lungs and exchanges the oxygen for CO2 at 
the muscular level, more specifically via the mitochondrial membrane of the muscle cell. 
However, the heart muscle itself also needs oxygen to perform its contracting force. The 
heart muscle receives its oxygen through the coronary arteries. At rest, the heart subtracts 
about 95% of the oxygen from the coronary arteries. The only option the heart muscle has to 
subtract more oxygen from the coronary arteries is to dilate its coronary artery vascular tree. 
Subsequently, the cardiac oxygen supply can increase five fold to meet the increased oxygen 
demand. In a normal situation, exercise is limited through a shift from aerobic to anaerobic 
metabolism. As a result of this metabolic change more effluents (lactate, potassium etc) are 
produced. These effluents activate chemical and mechanical receptors in the heart (among 
others TRPV1), conveying signals to the brain which result in withholding exercise, most 
often because of fatigue and dyspnea (vide infra). However, in the presence of coronary 
artery disease, the atherosclerotic plaque reduces the dilatory facilities of the coronary artery 
and so the aerobic threshold is reached much sooner. The (exercise) induced discrepancy 
between oxygen supply and demand is called myocardial ischemia. Stable angina comprises 
that the complaints of angina are induced during exercise. The heart muscle (myocardium) 
becomes ‘ischemic’ at the aerobic threshold at which the critical balance between oxygen 
(O2) supply and demand is perturbed (Figure 1). The metabolic demand of the heart is 
determined mainly by contraction force -build upon the amount of ATP energy storage- and 
the product of heart rate and systolic blood pressure, the so-called rate pressure product 
(RPP) or double product. The increase in O2 demand, as is required during cardiac stress, is 
proportional to the increase in the RPP.21  
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≠ =mismatch. HR= heart rate. RPP=rate pressure product; BP = blood pressure; ATP = adenosine 
triphosphate. 
Fig. 1. See text for details 
3.1 Ischemic heart disease 
The most common manifestation of ischemic coronary artery disease (CAD), the leading 
cause of death in the United States, is angina pectoris. In a substantial proportion (~10.2 
million) of the estimated 17.6 million affected American patients with obstructive CAD, 
angina has become the main clinical symptom.  
Many strategies have been developed to improve the ischemic capacity through reducing 
the demand (by means of, for instance, ǃ-blocking agents) or by improving the supply (by 
means of, for example, revascularization). Novel approaches are required to improve 
clinical outcomes in patients with coronary heart disease. To date the focus of antiischemic 
therapies is also on making the heart, i.e. the myocyte, more resistant to ischemic challenges 
by enhancing the ischemic threshold, which is determined by both collateral flow and 
preconditioning. These two alternatives improve the ischemic tolerance and will be 
discussed further. 
3.2 Cardiac microcirculation 
A pluriform array of mechanisms, including metabolic, neural and myogenic systems are 
involved in regulating blood flow within the coronary vascular tree; increases in blood flow 
involve corresponding increases in vessel diameter at the level of the small vessels and 
arterioles. In the heart, diminished oxygen delivery in response to myocardial ischemia is 
countered by an increase in regional blood flow and functional capillary density within the 
microcirculation. Under resting conditions only a small number of coronary capillary vessels 
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in the heart are open for blood flow; during exercise (increased oxygen demand) additional 
capillary vessels are opened (i.e., recruited). Understanding the various factors that control 
post-ischemic coronary capillary blood flow across the myocardial wall remains an important 
challenge. In the setting of coronary artery disease, maldistribution of blood flow is attributed 
to dysfunction of specific components of the vessel wall, in particular the endothelium. 
Of fundamental importance for post-ischemic tissue viability in the heart is the delivery of 
oxygen and nutrients, either via pre-existing coronary vascular or collateral networks or via 
promotion of new vessel growth (i.e., vasculogenesis or neovascularization). In a canine 
preparation of chronic myocardial ischemia, Kersten and co-workers documented that 
coronary collateral development in response to repeated coronary occlusions requires an 
extended timeframe for coronary collateral growth.22 These findings confirmed earlier results 
that coronary collateral conductance improved over time and was associated with increased 
transmural distribution of blood flow in the heart after brief coronary occlusion in the canine. 
Remodeling of existing small vessels by addition of vascular smooth muscle cells and 
extracellular matrix around a larger diameter may be important in formation of collateral 
vessels. There is ample reference to coronary collateral recruitment at onset of ischemia in 
the scientific literature. It would be more reasonable to use the terminology of microvessel 
or capillary recruitment (as suggested initially by Krogh in his capillary-tissue exchange 
cylinder model). He reported that opening of coronary collateral channels occurs in man 
during coronary occlusion.23a,b,c More recently ischemic adaptation to collateral channel 
opening was observed during ischemic preconditioning, which is thought to play an 
important role in the development of ischemic tolerance.24 In animal experiments “opening” 
of coronary collateral channels has not been documented;25 this would suggest that 
augmented blood flow to ischemic myocardium in animals via capillary vessels does not 
play a role in the cardioprotective actions induced by preconditioning. Consequently, 
experimental studies may not provide sufficient evidence to elucidate the underlying 
mechanisms of action of electrical neuromodulation in humans. 
3.3 Ischemic preconditioning (IPC) and postconditioning 
In their recent report on ischemic conditioning, described as “the practice of applying brief 
episodes of nonlethal ischemia and reperfusion to confer protection against a sustained 
episode of lethal ischemia and reperfusion injury”, the authors discuss this potentially 
therapeutic strategy.28 They noted that the protective stimulus can be applied before 
ischemic preconditioning (IPC), during the onset of sustained episodes of lethal ischemia 
(ischemic conditioning), or at the onset of myocardial reperfusion (ischemic post-
conditioning).” In brief, IPC is an intrinsic process, usually induced by repeated short 
periods of ischemia, most often performed through a temporary occlusion of a vessel, 
through pharmacological substances, or through exercise stress to protect the myocardium 
against a subsequent ischemic insult. The phenomenon was described first by Murry et al, in 
1986, exposing anesthetised dogs to 5 minutes of coronary artery occlusions, followed by a 5 
minute period of reperfusion and finally to a 40 minute continuous occlusion. In controls 
ischemic preconditioning was withheld. The control animals experienced larger infarct sizes, 
compared to the preconditioned dogs.26 IPC was initially thought to be the result of slower 
ATP-energy depletion, later interference with effectors of cell death, free radicals, 
attenuation of mitochondrial permeability and involvement of adenosine, opioid receptors 
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and connexin 43.27 Ischemic postconditioning, a series of mechanical interruptions of 
reperfusion after ischemia, is performed immediately after reperfusion, for protection of 
myocardium against infarction, secondary to ischemia and reperfusion damage.28 Albeit 
that basic evidence of conditioning is abundant, its clinical effect remains debatable since 
mechanism of action remain partly unraveled, making translation to patients still difficult. 
4. Methods of electrical neuromodulation for refractory angina 
4.1 A brief history of electrical neuromodulation methods  
The encouraging effects of electrical current for all kind of ailments have been in use since 
the pharaohs, Greeks and later the Romans. In ancient history physicians were aware of the 
power of  electrical current, provided for instance by the electric eel, to heal discomforts, like 
headache and gout.29 In the early nineteenth century stimulation of nerves to reduce pain 
was termed electro-analgesia or electro-narcosis.30 In 1965 the landmark study by Melzack 
and Wall was published. They proposed the model of the gate control,31 implying that 
electrical current applied to the myelinated, relatively fast conducting, thicker A-fibers, 
modulates the pain processing in the non-myelinated slower conducting C-fibers via 
interneurons in the dorsal horn, and so affects pain. Although the theory still stands, it is not 
tenable in all its aspects anymore. In higher brain centers, it was shown with positron 
emission tomography (PET) that angina affects areas involved in cardiovascular control.32 In 
patients with angina, active neuromodulation was unable to suppress the conduction of 
cardiac pain signals to the cerebrum, during cardiac distress.33 Comparison of these two 
studies demonstrated activation of the same cardiovascular control centers during active 
neuromodulation as were recruited following angina. At the cardiac level the intra-cardiac 
neurons (ICN) are considered as the final common pathway, integrating the peripheral 
nervous system with the heart. These ICN are hidden in the fatty patches on the heart, 
controlling cardiac function. The more central superimposed neural hierarchy, controlling 
the ICN, has been described in relation to the presence of myocardial ischemia, in detail.34 
The presence of this neural environment does not make an involved placebo unlikely in the 
field of electrical neuromodulation. In this regard, in the 1930s, Beecher coined and 
described nicely the placebo effect of, among others, surgical procedures in relation to 
intrinsic and extrinsic factors.35 Specifically for therapies like electrical neuromodulation, 
with a not entirely unraveled mechanism of action, it is important to note that the therapy is 
conspicious for placebo. To exclude placebo as the one and only factor explaining the effect 
of electrical neuromodulation, unraveling of mechanisms and performing well designed 
studies, such as randomized control studies, are of paramount importance. Though all 
therapies encounter a certain percentage of placebo, since the effects of electrical 
neuromodulation often last for years (vide infra) and since randomized control studies 
(RCT) also demonstrate beneficial outcomes, it is unlikely that a placebo is the only 
explanation for the favorable effects of electrical neuromodulation. Further, several studies 
have shown clear evidence of somatic cardiovascular responses resulting from spinal cord 
stimulation, such as, among others, alterations in activity of spinothalamic tract cells36 and of 
intra cardiac neurons37 and changes in blood pressure.38 
Over the last 50 years a number of techniques to produce electro-analgesia have been 
reported. We will briefly review these methods. 
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4.2 Stellate ganglion stimulation 
Dr Braunwald, a brilliant pioneer in cardiology and his late wife, a thoracic surgeon, modified 
a pacemaker device to stimulate the stellate ganglion. Already in 1967 they reported an anti-
angina effect using this method of electrical neuromodulation.39 In addition, they coincidently 
observed in a patient experiencing an acute coronary event, normalization of the ST-T 
segment, following active stimulation. However, in spite of the initial encouraging results, this 
method of neuromodulation was discarded in the beginning of the seventies, because coronary 
artery bypass grafting became widely available.40 In some centers, blocking of the stellate 
ganglion, by means of anesthetics, is still in vogue in specific circumstances.41 
4.3 Transcutaneous Electrical Nerve Stimulation (TENS) 
Since not all patients turned out to be suitable candidates for revascularization, a decade 
later clinicians started to use newer forms of electrical neuromodulation, such as TENS, to 
deal with the chest discomfort of patients. Neurostimulation for angina pectoris is usually 
performed by either Transcutaneous Electrical Nervous Stimulation (TENS) or by an 
implantable Spinal Cord Stimulator (SCS). Since 1982 TENS is considered as an effective 
method in the treatment of chronically disabled patients through reducing frequency and 
severity of the angina attacks and subsequently the necessity for the intake of short acting 
nitrates.42 In addition, to the improvement in quality of life, TENS also improved exercise 
capacity, and lactate production (vide infra).43 However, the drawback of TENS is that the 
plasters on the chest may induce ortho-ergic reactions (contact dermatitis) in 20-30% of the 
patients, come off during sweating and are difficult to attach on hairy chests or females with 
large mamma.44,45 So, these shortcomings often necessitate a withdrawn from TENS therapy. 
4.4 Spinal Cord Stimulation 
The story of electro-analgesia goes on with the introduction of dorsal column stimulation in 
1967,46 which later was renamed epidural spinal cord stimulation (ESES) and today is 
known as spinal cord stimulation (SCS). However, taking into account the surgical 
procedure, with respect to TENS, SCS seems to be more effective with more pronounced 
and sustained effects, long-term.47 In 1987, in the first report on the antianginal effect of SCS 
in patients with refractory angina, a reduction in both the frequency and severity of angina 
attacks was found, in conjunction with a reduction in sublingual intake of nitrogen tablets.48 
Later many authors advocated SCS as an effective strategy for patients with severe 
refractory angina. In addition, in patients with a high surgical risk, SCS is even considered 
as a substitute for coronary artery bypass surgery.65 
The implantation procedure of this reversible non-destructive therapy is comparable to the 
implantation of a pacemaker, though the electrodes are placed epidurally and not in the 
heart.  The success of SCS depends, among others, on the correct positioning of the 
stimulating electrode(s) in the dorsal epidural space. It is still considered mandatory that the 
paresthesias induced by the stimulator correspond with the area where most of the patients 
experience their angina. When the tip of the electrode of the SCS device is properly placed at 
C7-T2, the lead is anchored and connected to the implanted pulse generator (IPG). The IPG 
is positioned into a subcutaneously created pocket, in the chest, comparable with the 
placement of a pacemaker, or in the lower upper abdominal wall. The patient can 
(in)activate the IPG through a patient programmer or by application of a magnet. 
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The question was recently posed whether paresthesias are necessary for the beneficial effects 
of SCS. In this respect two studies have addressed this paradigm by randomizing patients to 
subthreshold stimulation and stimulation with induced paresthesias. The results were 
contradictory. In one study the investigators argued no difference between paresthesia 
induced stimulation and subthreshold, however the authors observed a significant 
difference with very low stimulation.49 In another recent study this observation could not be 
demonstrated in naive patients.50 
4.5 Subcutaneous Electrical Nerve Stimulation (SENS) 
Subcutaneously electrical neurostimulation (SENS), also called among others SubQ, 
subcutaneous target stimulation, peripheral nerve or peripheral field stimulation is a 
promising method.51 Recently, we and others have reported on the use of subcutaneous placed 
leads, implicating positioning of electrodes just underneath the thoracic skin, together with a 
subcutaneously implanted device. This method seems to be effective in the treatment of 
patients with therapeutically refractory angina.52,53 Patients with severe coronary artery 
disease, in which withholding anti-thrombotic pharmacotherapeutics is not feasible, may be 
excellent candidates for both subcutaneously implanted device and leads. Other drawbacks of 
the SCS treatment are that electrode placement into the epidural space is rather critical when 
compared to epidural placement. Furthermore, a physician with neuromodulation skills is 
needed for placement of the electrodes under fluoroscopy, though sometimes even then an 
unsuitable anatomy of the spinal area makes positioning of the electrodes impossible. So, 
theoretically SENS may be unifying the “best of two worlds”, including the better convenience 
in use (and efficacy?) of SCS over TENS and an implantation procedure which is more simple 
(cardiologists can do it themselves), possibly safer (considering the procedure) and, maybe at 
less cost (shorter operation procedure and lower thresholds), when compared to SCS.  
5. Electrical neuromodulation and angina 
To optimize and to tailor adjunct treatments for patients suffering from chronic refractory 
angina, a ‘care pathway’ for ‘patient-centered guiding’ has been developed.54 The experts 
propose to start with less invasive methods, such as rehabilitation and TENS, later followed 
by more invasive but reversible methods, such as SCS or SENS. Ultimately, destructive 
methods such as ablation of nerves may be carried out. 
Since the first publications, abundant articles have testified that electrical neuromodulation 
gained credentials in efficacy as an adjuvant therapy for in patients with severe refractory 
angina, irrespective of whether the method is applied at the skin of the chest,42,43 cervically55 
at the T1-4 thoracic level,56,57 or subcutaneously.52,55 To assess the efficacy of electrical 
neuromodulation among patients with refractory angina receiving the various forms of 
electrical neuromodulation, comparative randomized control studies are warranted. The 
studies ought to have a placebo controlled design.35 However, unfortunately the studies can 
not be blinded since the physician notifies the stimulation artifacts on the ECG and the 
patients are aware whether or not stimulation is present. These comparative studies have 
not yet been executed. However, there is scarce literature in open retrospective studies that 
SCS may be more effective than TENS.58 The results show that SCS is effective in 80% of the 
patients after a period of 4 years. After that same period, TENS is effective in about 60% of 
the patients. On the other hand to improve the outcome, it is important to develop the 
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screening before application of neuromodulation is started, since about 20% of the patients 
do not show improvement in quality of life following SCS implantation. 
Many observational (long-term) studies on electrical neuromodulation have consistently 
observed a reduction in angina complaints and use of short acting nitrates 59,61,62, with a 
subsequent improvement in exercise capacity 59,60,61,62 and quality of life.15,63,64 Quality of life 
measure, in this severely disabled group of patients, is usually executed by way of 
questionnaires (Nottingham health profile; Short Form-20 and RAND-36) and diaries (to 
score the daily number of angina attacks and number of NTG intake). These findings have 
been substantiated by observational studies and RCTs showing that the improvements may 
last for up to 10 years.60,61,63,64,65 These measures are, however, not taken co-morbidity and 
personality, which factors may affect outcome parameters, into account.66,67 
The major flaw of many of the clinical studies on electrical neuromodulation is the inborn 
weakness of all open observational designs, implicating one does not know how much bias 
is found in outcome parameters. On the other hand observation studies are very useful in 
presenting the ‘real world’, instead of reporting a limited number of highly selected 
patients, as is the case in randomized studies.68 Unfortunately, the greater part of studies 
regarding the subject of electro-neuromodulation for angina, are carried out with a limited 
number of patients. In this regard, two recent meta-analysis on randomized controlled trials 
(RCT) have been executed, showing significant improvements in both quality of life (Fig 2) 
and exercise duration (Fig 3). 69,70 
 
Fig. 2. Health related quality of life of 6 RCTs (adapted by R Taylor from ref. 70) 
In accord with its efficacy and safety, SCS has been included in 2002 into to the 
ACC/AHA guidelines as an additional therapy for the treatment of this group of patients, 
with a class 2 indication.71 
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All modalities of electrical neuromodulation are reversible. Mainly for medico-legal reasons, 
combination with other devices is not advocated.72 Divergent literature is available too, 
reporting on the safety in combination with artificial cardiac pacemakers73 and implantable 
cardioverter defibrillators when specific measures are taken into account.74  
With regard to the safety aspects of electrical neuromodulation, many worry as it might 
deprive the patients of their angina. In studies on patients with stable angina, all patients 
ultimately experienced angina.59 The fear for a potentially jeopardizing situation during an 
acute coronary syndrome, resulting from a suppressed conduction to the brain during active 
neuromodulation, does not seem to be justified, since electrical neuromodulation does not 
seem to block nociceptive information from the heart to the brain.33   
Accordingly electrical neuromodulation is not found to conceal complaints of angina during 
a myocardial infarction since the nociceptive information on ischemia from the heart to the 
brain is modulated but not abolished.75,76,77 Electrical neuromodulation, rather than 
eliminating angina normalized the, through sensitization enhanced, angina threshold. The 
patients therefore experience an increase in exercise capacity and a reduction in severity of 
symptoms of angina, which does not adversely affect mortality nor morbidity. Regarding 
mortality in the population of patients treated with SCS for refractory angina pectoris, 
several studies report a relatively low annual mortality rate of about 5-7%.13,78,79 We recently 
evaluated morbidity in this group of patients, by comparing medical history at baseline with 
follow-up data.66 Our interest in morbidity was generated by the lack of improvement in 
quality of life indices in a substantial number of patients, after long-term implantation of  
 
Fig. 3. Exercise tests of 7 randomized control studies (adapted by R Taylor from ref. 70) 
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spinal cord stimulator. We reported that in some patients the lack of improvement in quality 
of life was related to the presence of co-morbidities, such as respiratory diseases, 
musculoskeletal disorders, diabetes and obesity. As a consequence of our analysis of the 
effects of SCS on quality of life, we recommend that in studies on electrical 
neuromodulation, the effect of co-morbidities on the quality of life is taken into account. 
Several cost-benefit and cost-effectiveness studies have been performed to evaluate the costs 
of SCS in the treatment of refractory angina. The break-even point for costs is calculated to 
be about three to four years.80,81 
Given the data, electrical neuromodulation is considered as one of the best and safest 
adjuvant therapies to consider for patients suffocating from chronic refractory angina.82,83 
In conclusion, studies with different designs have consistently demonstrated that electrical 
neuromodulation reduces complaints of angina, enabling patients to prolong their exercise, 
independent of the method applied. Whether or not electrical neuromodulation may 
improve myocardial ischemia is the subject of the next part of this chapter. 
6. Electrical neuromodulation and myocardial ischemia 
In the wake of many favorable outcomes on quality of life end points assessed in studies 
with patients suffering from chronic refractory angina pectoris, treated with electrical 
neuromostimulation, the debate continues whether the raise in angina threshold is 
associated with an improvement in ischemic tolerance. 
In 1967 Braunwald et al, stimulating the stellate ganglion to achieve a reduction in 
complaints of angina, were the first to observe a concomitant reduction in myocardial 
ischemia during active stimulation.39,40 The beneficial effects of  electrical neuromodulation 
(TENS) on the resolution of ST-segment depression in patients suffering from and following 
an acute coronary syndrome were later confirmed by de Vries et al.84,85 However, in spite of 
the antianginal and antiischemic effect, electrical neuromodulation was used in a rather 
limited number of patients. The restricted number of patients treated was attributed to the 
introduction of bypass surgery, at that time, making neuromodulation outdated.40 In 
addition to the reduction in angina, induced through electrical neuromodulation exerted by 
means of stellate ganglion stimulation, its suggested antiischemic effect was later confirmed 
by making use of different methods, a variety of study designs, and end points. Using 
TENS, in the short-term limb of the study, a reduction was reported in lactated production 
and ST-T segment depression during pacing-induced and a long-term improvement in 
exercise capacity in conjunction with a persistent ST-T segment depression during maximal 
exercise stress tests.43 Unfortunately, in this respect not all studies on exercise capacity are 
assessing ST-T segment changes,86,87 since the recording requires either, specific filtering of 
the ECG signal or, temporarily withholding active stimulation during the exercise. This 
specific skill is related to interference of the neurostimulation induced artifacts on the ECG. 
Later, several observational and randomized studies, making use of this expertise to 
evaluate antiischemic effects of SCS, by means of bicycle or treadmill exercise stress tests as 
the method of choice, show consistent findings of a reduction in ST-T segment depression at 
maximal and at comparable work load, in conjunction with improvement in exercise 
duration. 57,59,61,62,63 So, in spite of a prolonged exercise duration the patients had less 
myocardial ischemia. However, in a meta-analysis of 5 randomized studies on exercise 
stress tests ST-T segment changes were not significantly altered, following SCS (Fig 4)  
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Some studies included in the meta-analysis used a subthreshold versus threshold stimulation, 
others used the design of stimulation versus no stimulation and others used stimulation versus 
active non-neurostimulation comparators.70 Of note, a study only examining the duration of 
the work out by a 6 minute walk test was excluded from the meta-analysis.88 
Furthermore, ambulatory ECG monitoring also showed a reduction in ischemic burden in 
daily life.61,89 Studies on SCS making use of ambulatory ECG recording are more difficult to 
perform because of the so-called carry-over effect.90 This observation was already reported 
in 1967 by Shealy et al, coining the phenomenon “post-stimulation prolonged analgesia after 
discharge”.91 The investigators reported that after subcutaneously electrical stimulation of a 
peripheral nerve, the central response continues for seconds up to a minute, depending among 
others on the duration of stimulation. Later Armour and coworkers showed this latency 
following electrical nerve stimulation, also to occur in the intra cardiac neurons, in the 
presence of myocardial ischemia.92 Jessurun et al demonstrate that this post-analgesic effect 
may even last for weeks.93 This prolonged stimulation effect may affect study outcomes. 
Moreover, specific filters are required to reduce the stimulation artifacts on the ECG. 
 
Fig. 4. Ischemic burden evaluated in 4 randomized studies (by R Taylor) 
In this regard, studies on right atrial pacing showing a delayed onset of angina following 
active SCS also substantiates the antiischemic effect of electrical neuromodulation by 
reporting a reduction in ischemia at maximal exercise during active SCS and a concomitant 
reduction in lactate production.94 
So, albeit that electrical neuromodulation has been found in both observational and 
randomized studies, using sequential ECG recordings, exercise stress tests at comparable 
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and maximal work load, and ambulatory ECG recordings, to significantly improve ST-T 
segment depression, considered as a marker for myocardial ischemia, these findings raise 
the question which neurocardiological mechanisms are involved. Therefore, electrical 
neuromodulation was used to examine the neural hierarchy in cardiac control.2,34 
Initially, the favorable effects of SCS, for other indications than angina, were attributed to a 
sympathicolytic effect.75  
In 1950 Lindgren was the first to report on beneficial outcomes of bilateral upper cutting of 
the thoracic sympathetic nerves in patients suffering from severe angina.95 Later modulation 
of nerves became more accepted than the destruction of nerves. Meglio et al demonstrated a 
reduction in heart rate in 25 patients without overt cardiac disease with a spinal cord 
stimulator, implanted for pain.96 However, their early experimental finding has never been 
substantiated by others. 
In current pharmacotherapeutical treatment of angina, ß-blocking agents have become a 
cornerstone for 45 years.97 ß-Blocker agents employ their beneficial result through their 
effect on the sympathetic nervous system and the subsequent decrease in rate pressure 
product (RPP). This reduction in RPP results in a decline in myocardial oxygen demand.  
Initially, the antiischemic effect of SCS was also subscribed to modulation of the autonomic 
nervous system, more specifically to the sympathetic limb. 
Ambulatory ECG recording have not shown a change in Heart Rate Variability (HRV), a 
measure of autonomic function, following electrical neuromodulation.89,98 In the setting of 
patients with angina, the lack of influence of SCS on HRV may be caused by the blunting 
effect of ǃ-blockers on HRV in the majority of patients with angina. 
Furthermore, there is scarce evidence that SCS is still active after sympathectomy (Dr Juhl G, 
Danmark, personal communication), no change in cardiac epinephrine spill-over was found 
94,99 and SCS does not seem to affect adrenergic function as assessed by single photon 
emission computed tomography either (11)C-hydroxyephedrine or iodine 123- meta-iodo-
benzylguanidine in patients with coronary artery disease,100 or in patients suffering from 
chest pain during exercise induced ST-T segment changes but, without significant coronary 
artery disease (i.e. cardiac syndrome X).101 
So, in the treatment of angina with SCS, clinical data do not support the hypothesis that 
electrical neuromodulation employs a ǃ-sympaticolytic effect. The lack of sufficient evidence 
of a ǃ-adrenergic effect of electrical neuromodulation does, of course, not exclude an ǂ-
sympathetic effect to be involved in changes in myocardial perfusion (vide infra).102 There is 
basic evidence that SCS enhances the vagal tonus.103 In concert with this observation, a study 
in patients with severe coronary artery disease demonstrates that vagal stimulation, inhibiting 
norepinephrine release from sympathetic nerves to the heart, may subsequently alter the 
sympatholytic/ vagotonic balance and so dilates cardiac microcirculatory vessels.104 
Mannheimer and coworkers put forward the hypothesis that electrical neuromodulation  
reduces the myocardial oxygen demand.94 Based on the observed reduction of ST-T segment 
changes at comparable work load (i.e. same RPP) the researchers hypothesized that the 
decrease in myocardial oxygen demand subsequently reduces symptoms associated with 
angina pectoris.59 This hypothesis suggests involvement of a sympathicolytic effect. In 
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addition, in their rapid atrial pacing study, the investigators showed an improvement in 
ischemic threshold during pacing induced ischemia in the presence of active SCS. In a letter 
to the editor of the British Medical Journal preconditioning as alternative explanation was 
proposed. 105  The authors based their theory on the short term between the experiment with 
and without SCS. In addition to ischemic preconditioning the heart is also protected during 
reperfusion by ischemic postconditioning, which protects the heart after the manifestation of 
the ischemic event through signal transduction pathways. In concert with the ‘cardiac 
conditioning hypothesis’, more plausible concepts than the reduction in myocardial oxygen 
demand following SCS have been postulated. These concepts are based on alterations in 
myocardial blood flow and subsequently in affecting myocardial perfusion. 
To measure the effects in myocardial perfusion induced through electrical neuromodulation, 
studies have been performed with both, radionuclides and Doppler flow wires. In a study 
with 740 MBq 99-Technetium-MIBI an improved flow was reported in 16 out of 27 patients, 
only after 1 year. 106 In 10 patients no change was showed in myocardial blood flow and in one 
patient myocardial blood flow worsened after one year. Since, after 3 months, the investigators 
reported significant improvements in symptoms of angina, but not in myocardial perfusion, 
and after one year myocardial ischemia also improved, they concluded that “symptomatic 
relief precedes improvement of myocardial blood flow”. In contrast to Mannheimer et al,94 
noticing in their rapid atrial pacing study an instantaneous reduction in myocardial ischemia, 
followed by a relief in angina, during SCS, in the latter study with MIBI-SPECT nuclide, a 
reduction in myocardial ischemia was observed only after one year. The discrepancy in latency 
of effects may be related to two different mechanisms. 
To further evaluate the influence of SCS on myocardial ischemia, Fricke and co-workers 
performed a Positron Emission Tomography (PET) study with 18F-FDG as tracer to detect 
changes in viability and 13N-ammonia as tracer for coronary flow reserve in patients with 
an implanted SCS for refractory angina.107 Irrespective of the improvement in clinical 
symptoms, the investigators failed to demonstrate significant alterations in coronary flow 
reserve. In contrast to their findings, two other observational studies, using 13NH3 as tracer 
in patients with spinal cord stimulator implanted for refractory angina, reported blood flow 
directed from normally perfused regions to ischemic myocardial areas, in conjunction with 
an improvement in coronary flow reserve, resulting in a more homogenous perfused 
myocardium.108, 109  This discrepancy in outcomes of the PET studies is thought to be related 
to differences in methodology, tracers, protocols and, tools. Furthermore, the redistribution 
in coronary blood flow from normally perfused to impaired perfused regions has also been 
observed following the administration of aminophyline, theofylline or bamiphylline and 
was coined “the Robin Hood phenomenon” (stealing from the “rich” non-ischemic areas 
and supplying the blood to the “poor” ischemic regions).110, 111  All these three drugs are 
affecting adenosine handling through their interaction with Xanthine metabolisme. Further, 
the adenosine re-uptake inhibitor dipyridamole blunts the effect of SCS 108 and the drinking 
of caffeine too has been reported to reduce the effects of neuromodulation through its effect 
on adenosine, via xanthine metabolism.112 
Adenosine, administered in a coronary artery provokes angina through activation of 
adenosine A1 receptors.113,114  Adenosine plays a role in myocardial ischemia as well, which 
effect is thought to take place through activation of the A2 adenosine receptor, generating in 
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its turn, under ischemic conditions, redistribution of local blood flow from sub-epicardial 
towards epicardial tissues.115 So, the moment the critical balance between myocardial 
oxygen supply and demand is deferred, by either improving supply, or through a reduction 
in demand, a cascade of chemical reactions take place. It is conceivable that electrical 
neuromodulation employs its effect through interference with local adenosine handling. 116 
In addition to the increased angina threshold, which was first addressed in the rapid atrial 
pacing study in patients with a SCS implanted for their angina,94  the observed antiischemic 
effects of SCS resluted in improvement of ischemic tolerance. Since the ischemic tolerance is 
considered as the result of collateral recruitment and preconditioning, the emphasis of the 
research was aimed at these two phenomena, in detail. 
To unravel the mechanisms of action of electrical neuromodulation in cardiac performance, 
research was performed to the measuring of changes in coronary blood flow with Doppler 
flow catheters. In 1994, Chauhan et al showed an increase in coronary flow velocity in 
patients with refractory angina, during only 5 minutes’ TENS.117 In contrast to their 
findings, observations in an anesthetized canine preparation of SCS, in which myocardial 
ischemia was created through a 4 minute ligation of a coronary artery, followed by 
application of radiolabeled microspheres to evaluate myocardial ischemia, suggest that 
blood flow in the microcirculation was not affected.118 Albeit that the occlusion was of 
very short duration and the canines did not show atherosclerotic coronary artery disease, 
this finding should not be surprising since it has been shown that the sympathetic 
nervous system does not seem to influence native coronary collateral vessels in canine 
myocardium. Other studies using Doppler flow wires confirm the initial results,119 most 
likely resulting from altered coronary collateral blood flow by a so-called reversed steal, 
following electrical neuromodulation.120 After the pilot phase, the recruitment of 
collaterals was demonstrated in a randomized control study during percutaneous 
coronary intervention and only 5 minutes of TENS.121 The altered coronary blood flows 
does not necessarily require an increase in blood flow velocity.122 
The other branch to improve the ischemic tolerance of the heart, (pre)conditioning, has too 
been subjected to mechanistic studies.28 Initially, preconditioning was hypothesized to be 
induced through activation of protein kinase C cascade, which phosphorylates the 
mitochondrial ATP-sensitive K+ channels. This signalling pathway leads to preconditioning 
through a more gradual depletion of ATP-dependent energy storage mechanism. In the 
present concept of preconditioning, several signaling pathways play a role. Activation of 
signaling pathways are suggested to take place through release of substances like 
neurotransmitters and vasoactive compounds, such as adenosine and endorphins. 
Adenosine has vasodilatory effects and is involved in nociception. Therefore, it was 
postulated that adenosine may be the interface between neurohumoral and cardiovascular 
interactions. As a result of coffee intake and dipyridamole the metabolic handling adenosine 
appears to be affected, in the presence of electrical neuromodulation.108,112 Finally, electrical 
neuromodulation has been demonstrated both, to release beta-endorphins from the heart123 
and to affect the alpha-receptor.124 These three prerequisites are all involved in the 
upregulation of G protein-coupled receptors which, in turn, activate ATP-sensitive K+ 
channels, through up-regulation of protein kinase C. In an experimental set up it was 
demonstrated that electrical neuromodulation mitigates transient ischemia in anesthetized 
rabbits. The animals were all subjected to 30 minutes of coronary arterial occlusion, followed 
www.intechopen.com
 
Topics in Neuromodulation Treatment 
 
158 
by 3 hours of reperfusion, in the presence or absence of SCS at C8-T2. Pre-emptive electrical 
neuromodulation was able to reduce the ischemic zone, significantly, which effect was 
eliminated by ǂ-receptor blockade. A polymerase chain reaction showed an increased 
phosphorylation of cardiac protein kinase C. This protein is known for its role in 
preconditioning. Furthermore, electrical neuromodulation did not seem to affect blood 
pressure or heart rate. It was concluded that pre-emptive electrical neurostimulation 
reduces the size of infarcts induced by transient coronary artery occlusion, which 
cardioprotective effect involves cardiac adrenergic neurons.124 
Both limbs involved in ischemic tolerance, collateral recruitment and preconditioning may 
engage similar signaling pathways at time of myocardial reperfusion, i.e. protein kinase 
cascades. 
In conclusion, based on enhanced ischemic tolerance it is conceivable that electrical 
neuromodulation employs its antiischemic cardioprotective effect by improving collateral 
flow, enhancing preconditioning and subsequently reducing myocardial oxygen demand. 
7. Final conclusions 
Electrical neuromodulation is an effective adjuct treatment for patients with refractory 
angina. Many studies showed that it is improving the quality of life of these patients who 
are severely disabled by their ischemic heart disease and also enhances the ischemic 
threshold. The antiischemic effect is thought to take place through activation of mechanisms 
which induce both preconditioning and recruitment of collaterals, without either increasing 
mortality rate and without concealing the angina warning signal, during an acute 
myocardial infarction. Therefore, neuromodulation is considered as a safe therapy for 
patients invalidated by their refractory angina. The underlying mechanisms of action are 
multi-factorial and take place at different levels in heart brain axis. 
8. Future developments 
Electrical neuromodulation for refractory angina is lacking a feed-back option, such as is the 
case in a pacing device, in which you can measure the threshold through assessing the capture. 
The determination of objective signs of an effect shall make the therapy more widely accepted. 
Notwithstanding the shortcomings, the use of various applications of electrical 
neuromodulation for a myriad of indications will develop further. It is conceivable that for 
transcutaneous nerve stimulation, instead of the pads that easily come off,  a shirt with built-in 
pads will be developed. Further, a combination of electric devices such as a spinal cord 
stimulator and an ICD are likely. The spinal cord stimulator may stimulate prior to the ICD to 
reduce the sometimes freighting discharge of the ICD for the patient. Finally, newer cardiac 
indications such as in the treatment for tachy-arrhythmias, heart failure, cardiac syndrome X 
(microvascular angina) and acute coronary syndromes will be evaluated. 
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